P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)
P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) is a paper indexed in PICO Portal from OpenAlex.
How many citations does P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) have?
P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) has 2 citations in the OpenAlex counts PICO Portal stores.
When was P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) published?
P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) has 2023 year in the PICO Portal index.
What is the open-access status of P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)?
P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) has closed oa status in the PICO Portal index.
What is the DOI of P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)?
The DOI for P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) is on the source record.
What is the OpenAlex record for P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)?
The OpenAlex for P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA) is on the source record.